No Data
Hong Kong stocks concept tracking | IP derivatives meet current consumer needs. The cereal economy games and film and animation IPs occupy a major position (including concept stocks).
According to Gamma Data, representative IPs in the gaming industry have achieved revenue exceeding 200 billion yuan.
Hong Kong stock market midday review | The hang seng index rose 0.49% in the morning session, and medical devices stocks strengthened collectively.
Medical device stocks are collectively strengthening, product procurement is quickly recovering, and institutions indicate that a large number of orders for trade-ins are expected in the fourth quarter.
Hong Kong stocks movement | zx inc (09890) surged over 20% with increased volume. The company is actively laying out diversified products, and the incremental business is expected to deliver better-than-expected performance.
zx inc (09890) surged more than 20% on heavy volume, as of the time of publication, it increased by 18.87%, trading at 8.44 Hong Kong dollars, with a turnover of 0.125 billion Hong Kong dollars.
Hong Kong stocks unusual movement | zx inc (09890) rose more than 15% against the market trend. "Douluo Continent: Legend of the Exorcism" will officially start open beta this Thursday.
zx inc (09890) rose more than 15% against the market, as of the deadline, up 15.48%, closing at 13.24 Hong Kong dollars, with a turnover of 44.5853 million Hong Kong dollars.
格隆汇公告精选(港股)︱北海康成-B(01228.HK): CAN103, used to treat Gaucher's disease (GD), obtains priority review qualification.
【Today's Focus】Beihai Kangcheng-B (01228.HK): CAN103 for the treatment of Gaucher's Disease (GD) granted priority review qualification Beihai Kangcheng-B (01228.HK) announcement, CAN103 (Velaglucerase Beta) for the treatment of Gaucher's Disease (GD) has been granted priority review qualification by the National Medical Products Administration Drug Approval Center. The granting of priority review qualification to CAN103 (Velaglucerase Beta) recognizes the urgent medical needs of GD patients in china and the advantages of the company's clinical trial results. The company is making every effort to accelerate the approval process of CAN103 (Velaglucerase Beta) to make it the first one.
ZX Inc. Unveils New Game Beta Test Launch
No Data
No Data
